Every 10-Q that CareDx, Inc. (CDNA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CDNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDNA filings page.
CareDx, Inc. reported a strong turnaround for the quarter ended June 30, 2026. Revenue reached $132 million, up 52% year-over-year, led by testing services revenue of $100 million on 17% higher volume and richer reimbursement, including $16 million of prior-period revenue. Patient and digital solutions contributed $19 million and lab products $13 million. Net income was $111 million, compared with a $9 million loss a year earlier.
The company closed the sale of its lab products business, receiving approximately $171.7 million and recognizing a gain of about $113.0 million, which also drove operating cash flow of $31 million and period-end cash, cash equivalents and restricted cash of $374,157 thousand. Subsequent to quarter end, CareDx acquired Naveris for $161.8 million in cash plus up to $100.0 million in earn-outs, expanding its specialty oncology footprint. Key risks include heavy reliance on Medicare, which represented about 30% of revenue, and ongoing patent litigation with potential exposure of up to $96.3 million plus interest.
CareDx, Inc. reported a strong turnaround for the quarter ended March 31, 2026, with revenue of $117.7 million, up 39% year-over-year, and net income of $2.8 million versus a loss a year ago. Growth was driven mainly by a 48% rise in testing services revenue to $91.4 million and 17% higher test volumes of about 54,900. Patient and digital solutions revenue rose 33% to $16.0 million, while product revenue declined 4% to $10.3 million. Operating cash flow improved to $4.3 million, and CareDx ended the quarter with $198.1 million in cash, cash equivalents and marketable securities and no debt. Subsequent events include an agreement to sell its lab products business for $170 million, a planned $160 million cash acquisition of Naveris plus up to $100 million in earnouts, and authorization of an additional $100 million share repurchase program.
CareDx, Inc. reported stronger quarterly results for the three months ended September 30, 2025. Revenue rose to $100.1 million from $82.9 million a year ago, driven by testing services ($72.2 million), products ($12.5 million), and patient and digital solutions ($15.4 million). The company posted net income of $1.7 million (diluted EPS $0.03), compared with a net loss of $10.6 million in the prior-year period.
Year‑to‑date, revenue reached $271.4 million with a net loss of $17.2 million. Cash and cash equivalents were $91.4 million and short‑term marketable securities were $102.8 million as of September 30, 2025. The company repurchased 5.0 million shares for a total of $75.6 million under its February and May 2025 programs, and had $24.4 million remaining under the May authorization. CareDx recorded an accrued litigation settlement expense of $20.25 million related to a securities class action, with $14.9 million in expected insurance proceeds recorded in prepaid assets. In the Lanham Act case against Natera, the appellate court affirmed liability and damages; no receivable was recorded. Management noted a material weakness in internal control remained unremediated as of September 30, 2025.